Notable Labs Ltd (NTBL): Net earnings per share growth forecast for next year
Notable Labs, Ltd. (NTBL) is implementing AI to personalize therapy for hematological diseases. The GURU.Markets platform reflects analyst expectations for N+1 profit dynamics, where the indicator reached -47.00, capturing market optimism. Notable Labs, Ltd. (NTBL) generates revenue through predictive live-cell testing to select effective chemotherapy. Growth prospects rely on the automation of cell screening to accurately forecast patient response.
Analytical breakdowns and data insights for company Notable Labs (NTBL)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
Total Debt to Capital Notable Labs, Ltd.|NTBL - Long-Term Debt to Capital|Short-Term Debt to Capital Notable Labs Inc.|NTBL - Company Debts|Debt to Book Capitalization Ratio Notable Labs Ltd|NTBL - Company Long-Term Debt|Company Short-Term Debts Notable Labs|Quick Liquidity Indicator notablelabs.com
- net income and valuation ratios data:
NTBL - Final Profit|Expected Profit Notable Labs, Ltd.|NTBL - Price to Earnings Ratio|Forward P/E Multiple notablelabs.com|NTBL - PEG Multiple|EV/EBITDA Multiple Notable Labs Ltd|NTBL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Notable Labs|NTBL - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months notablelabs.com|NTBL - Earnings per share increase in current year|Net earnings per share growth forecast for next year Notable Labs, Ltd.
- total revenue and sales volume data:
Summary company analysis:NTBL, Notable Labs, Ltd.
Investors assess business resilience through future revenue dynamics, utilizing this indicator as an aggregated forecast for next year's earnings per share (EPS) change. By analyzing expectations for net earnings per share, one can evaluate the impact of clinical validation costs for the Notable Labs, Ltd. (NTBL) IT platform and the risks of partner R&D budget cuts on the company's final profitability.
Key competitors
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Candel Therapeutics, Inc. (CADL)|Earnings growth forecast for next year Accuray (ARAY)|Net earnings per share growth forecast for next year SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|HURA: Net earnings per share growth forecast for next year|TARA (Protara) - Expected earnings per share growth for next year|Fate Therapeutics, Inc. - Expected earnings per share trend next year|WHWK (aadibio.com) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Champions Oncology (CSBR)|XBiotech - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Consensus forecast of earnings per share growth for next year OS Therapies (OSTX)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics|ANL (adlainortye.com) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Veru Pharma|TPST (Tempest Therapeutics Inc) - Earnings growth forecast for next year|Xilio Therapeutics, Inc. (XLO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Enochian BioSciences (RENB)|MURA: Net earnings per share change forecast for next year|Earnings growth forecast for next year KAPA (kairospharma.com)|Consensus forecast of earnings per share growth for next year OnKure (OKUR)|CytoMed Therapeutics Ltd - Earnings growth forecast for next year|curis.com (CRIS) - Expected earnings per share growth for next year|Apollomics Corp (APLM) - Net earnings per share growth forecast for next year|Tharimmune - Expected earnings per share trend next year|ADVB (Advanced Biomed Corp) - Earnings growth forecast for next year|Expected earnings per share growth for next year Genprex, Inc (GNPX)|Earnings growth forecast for next year CLDI|SBFM: Net earnings per share change forecast for next year|Earnings growth forecast for next year XBIO (xeneticbio.com)|Earnings growth forecast for next year Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Earnings growth forecast for next year|Expected net earnings per share growth next year American Oncology Network, Inc.|BGNE: Earnings growth forecast for next year|Expected earnings per share growth for next year checkpointtx.com|Net earnings per share growth forecast for next year Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Ikena (IKNA)|Earnings growth forecast for next year Viracta Therapeutics Inc. (VIRX)|Net earnings per share growth forecast for next year MorphoSys Inc MOR|Expected earnings per share trend next year NAYA|AAPGV: Expected earnings per share growth for next year
